EC approves GSK’s Menveo vaccine presentation for IMD
5 天之前 · GSK’s Menveo vaccine protects against invasive meningococcal disease. Credit: MAXSHOT.PL/Shutterstock. The European Commission (EC) has granted approval for a single-vial, fully liquid presentation of GSK ‘s Menveo vaccine (MenACWY), designed to protect against invasive meningococcal disease (IMD) caused by bacterial serogroups A, C, W and Y.
GSK’s fully liquid Menveo meningococcal vaccine approved by …
6 天之前 · About Menveo. GSK’s MenACWY vaccine has received regulatory approval in over 60 countries. 9 It offers evidence of immunogenicity with a well-characterised safety profile. 10,11 In the European Union (EU), this vaccine has received regulatory approval for active immunisation to prevent IMD caused by Neisseria meningitidis serogroups A, C, Y ...
6 天之前 · GSK plc (LSE/NYSE: GSK) today announced that the European Commission (EC) has approved a single-vial, fully liquid presentation of Menveo (Meningococcal Group A, C, W-135 and Y conjugate vaccine, MenACWY vaccine) to help protect against invasive meningococcal disease (IMD) caused by bacterial serogroups A, C, W and Y.
TOP NEWS: GSK hails EU Approval of Menveo vaccine in new …
6 天之前 · (Alliance News) - GSK PLC on Wednesday said its meningitis vaccine, Menveo, has received approval from the European Commission in a new single-vial, fully liquid presentation. In 2022, the London ...
GSK granted EC approval for meningococcal disease vaccine Menveo
4 天之前 · GSK also has an investigational five-in-one meningococcal vaccine in its pipeline which combines the antigenic components of Menveo and its approved meningococcal group B vaccine Bexsero. The candidate, MenABCWY, was accepted for regulatory review by the US Food and Drug Administration in April, following positive results from a phase 3 trial ...
GSK's Liquid Meningitis Vaccine Gets EU Authorization
6 天之前 · GSK's liquid meningitis vaccine, Menveo, received approval from the European Commission to be sold in the European Union. The British pharmaceutical company said Wednesday that the fully liquid ...
US FDA approves Menveo in a new single-vial presentation to help ... - GSK
2022年10月17日 · The Menveo vaccine (supplied in a two-vial presentation) for meningococcal groups A, C, Y, and W has been approved in over 60 countries, with more than 72 million doses distributed worldwide since 2010. It offers extensive evidence of immunogenicity and a well-characterised safety profile.
US FDA approves Menveo in a new single-vial presentation to help ... - GSK
2022年10月17日 · The Menveo one-vial presentation now comes in a ready to use single vial giving healthcare providers a more convenient option. The Menveo one-vial presentation will initially be available to US federal customers, with broader availability anticipated in mid-2023.
GSK’s fully liquid Menveo meningococcal vaccine approved by …
5 天之前 · GSK plc announced that the European Commission (EC) has approved a single-vial, fully liquid presentation of Menveo (Meningococcal Group A, C, W-135 and Y conjugate vaccine, MenACWY vaccine) to help protect against invasive meningococcal disease (IMD) caused by bacterial serogroups A, C, W and Y
GSK hails EU Approval of Menveo vaccine in new format
6 天之前 · (Alliance News) - GSK PLC on Wednesday said its meningitis vaccine, Menveo, has received approval from the European Commission in a new single-vial, fully liquid presentation.